bioRxivCancer Biology
KDM6A Regulates Immune Response Genes in Multiple Myeloma
D. Dupere-Richer, A. Riva, S. Maji, B. G. Barwick, H. Casella, A. Sobh, G. Quickstad, J. Li, u. de, C. Piper, M. Kulis, T. Ezponda, I. Martin-Subero, G. Tonon, W. Zhang, C. Mitsiades, L. H. Boise, R. L. Bennett, J. D. Licht
Abstract
The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of MHC expression, offering a strategy to restore immunogenicity of KDM6A deficient tumors. Loss of Kdm6a in murine RAS-transformed fibroblasts led to increased growth in vivo associated with decreased T cell infiltration. Statement of significanceWe show that KDM6A participates in immune recognition of myeloma tumor cells by directly regulating the expression of the master regulators of MHC-I and II, NLRC5 and CIITA. The expression of these regulators can by rescued by the HDAC3 inhibitors in KDM6A-null cell lines.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- assay: ChIP-seq
- research focus: host-pathogen & immune response
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells
Julian Schliehe‐Diecks, Jia‐Wey Tu, … Sanil Bhatia·Cell Death and DiseasePeer-reviewed·Mar 7, 2026
- KDM5A enhances MHC-I antigen presentation and potentiates antitumor immunity unleashed by immune checkpoint blockade
Dan Li, Chi He, … Xuebin Liao·bioRxiv·Jun 5, 2025
- MAPK ERK5 Is a Novel Regulator of MHC-I in Cancer Cells
Maria Viñas-Casas, José Miguel Lizcano·Cell Communication and SignalingPeer-reviewed·Mar 9, 2026
- Inhibition of KDM5A/B promotes antitumor innate immune responses in HHV-8/KSHV-positive B-cell lymphomas
Dawei Zhou, Guillaume N. Fiches, … Netty G. Santoso·npj VirusesPeer-reviewed·Aug 22, 2026
- KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition
L. D. Boila, S. Ghosh, … A. Sengupta·bioRxiv·Jul 12, 2022
- CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma
Xiangao Huang, David S. Jayabalan, … Selina Chen‐Kiang·bioRxiv·Oct 14, 2025